Update from Dr. Rashmi Kothary
Cure SMA Canada Funded Canadian Researcher Dr. Rashmi Kothar Ottawa Hospital Research Institute Biosketch: Dr. Kothary is the Deputy Scientific Director and Senior Scientist at the Ottawa Hospital Research Institute…
Cure SMA Canada Funded Canadian Researcher Dr. Rashmi Kothar Ottawa Hospital Research Institute Biosketch: Dr. Kothary is the Deputy Scientific Director and Senior Scientist at the Ottawa Hospital Research Institute…
Biogen announces the Health Canada is reviewing Spinraza – Jan 5, 2017. For late breaking details about Spinraza, check the Cure SMA (US) research news page and the Spinraza page,…
Donate A Car Canada accepts vehicle donations for “Cure SMA Canada”. To donate a car, truck, RV, boat, motorcycle or other vehicle to the Cure SMA Canada ”, go to…
CALLEN’S FIRST BIRTHDAY TOY DRIVE FROM JUNE 1ST TILL JUNE 14THThis is an online event and u can participate now until Callen’s birthday when we will close orders. Please join…
FDA approves Spinraza (nursinersin) for treating SMA – Dec 2016. Canadian locations were part of the clinical trials. There are many more details at the Cure SMA (USA) research review…
Title: The Non-SMN Mediated Benefits of The HDAC Inhibitor Trichostatin A PI: Rashmi Kothary We have just completed the first year of funding from FSMA Canada. Objective: Our goal was…
Objective: We will study and obtain more information about the role of a novel protein, called PRMT8, which is present at the surface of the cells that are most affected…
CARLSBAD, Calif., June 11, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants with Type…
Identification and Characterization of Factors Critical in Regulating the Selective Vulnerability of Distinct Motor neuron Pools in Spinal Muscular Atrophy Models of Mice 2013
This study will be recruiting shortly, and is open to qualifying Type 1 Infants. Canadian location is Toronto Hospital for Sick Children. From Cure SMA-US: ISIS Pharmaceuticals Initiates Clinical Study…